Clinical Trials Logo

Blindness clinical trials

View clinical trials related to Blindness.

Filter by:

NCT ID: NCT01793168 Recruiting - Clinical trials for Retinitis Pigmentosa

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

CoRDS
Start date: July 2010
Phase:
Study type: Observational [Patient Registry]

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access. Visit sanfordresearch.org/CoRDS to enroll.

NCT ID: NCT01754103 Recruiting - Blindness Clinical Trials

Neuroplasticity in Blind Subjects After Repetitive Tactile Stimulation

Start date: January 2012
Phase: N/A
Study type: Interventional

Brain plasticity of cortical activity caused by repetitive tactile stimulation could have a progressive development that was from primary parietal areas, passing over parieto-occipital areas and came secondary to primary occipital areas. This process allows to understand the existence of neurons in the brain and specific areas for certain functions independent of the type of stimulation is performed. By performing repetitive tactile stimulation over a period of 3 months,using a tactile stimulator, our group will try to prove several that repetitive tactile stimulation can create cross-modality and improve recognition and localization of patterns in blind people.

NCT ID: NCT01645306 Completed - Stroke Clinical Trials

Revacept in Symptomatic Carotid Stenosis

RevaceptCS02
Start date: March 8, 2013
Phase: Phase 2
Study type: Interventional

Patients suffering from symptomatic carotid artery stenosis, transient ischemic attacks (TIAs), amaurosis fugax or stroke receive either Revacept (single dose) plus antiplatelet monotherapy or monotherapy alone. Patients receive a single dose of trial medication by intravenous infusion for 20 minutes. Patients are followed up one and three days after treatment, at 3 months and by a telephone interview at 12 months.

NCT ID: NCT01614171 Withdrawn - Clinical trials for Osteoporosis Pseudoglioma Syndrome

Growth Hormone for Osteoporosis Pseudoglioma Syndrome

GHOPPG
Start date: December 2013
Phase: N/A
Study type: Interventional

Osteoporosis pseudoglioma (OPPG) syndrome is a rare autosomal recessive condition of childhood osteoporosis and congenital blindness for which new treatments are needed. We have found that body fat is increased in OPPG and muscle mass is reduced. We hypothesize that growth hormone therapy will improve muscle mass and bone strength in OPPG.

NCT ID: NCT01488786 Completed - Blindness Clinical Trials

A Study to Evaluate the BrainPort® Vision Device in Subjects Who Are Blind

Start date: October 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the safety of the BrainPort vision device and to demonstrate improved object recognition and word identification and ambulation with use of the BrainPort vision device in subjects who are medically documented as blind, with acuity of 20/ 5000 or worse.

NCT ID: NCT01256489 Withdrawn - Clinical trials for Stevens-Johnson Syndrome

Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

Start date: December 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The proposed study is intended to test the idea, based upon current knowledge of the biology and physiology of corneal ulceration in SJS/TENS patients who receive a keratoprosthesis, and on the known effects of infliximab on matrix metalloproteinases, that infliximab therapy for such patients may reduce the likelihood of corneal ulceration, and hence extend the period of prosthesis retention and vision recovery.

NCT ID: NCT01219569 Completed - Blindness Clinical Trials

Effects of Sevoflurane and Propofol on Light Flashed Evoked Pupillometry

Start date: August 2007
Phase: N/A
Study type: Observational

This is a study to focus on the feasibility of using a monitor which may signal loss of visual function intraoperatively.

NCT ID: NCT01208389 Active, not recruiting - Clinical trials for Leber Congenital Amaurosis

Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2

Start date: November 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The study is a follow-on to a Phase 1 dose-escalation and safety study.

NCT ID: NCT01203436 Completed - Clinical trials for Retinopathy of Prematurity

Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity

STOP-ROP
Start date: February 1994
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this trial was to determine the efficacy and safety of supplemental therapeutic oxygen for infants with prethreshold retinopathy of prematurity (ROP) to reduce the probability of progression to threshold ROP and the need for peripheral retinal ablation.

NCT ID: NCT01109576 Completed - Deafness Clinical Trials

Workshops for Veterans With Vision and Hearing Loss

DSLW
Start date: November 2011
Phase: Phase 0
Study type: Interventional

This is a pilot study of workshops to help Veterans with both vision and hearing loss live a happier, fuller and less stressful life. The results will be used to guide the development of a large scale clinical trial.